콘텐츠로 건너뛰기
Merck
  • Blockade of γ-Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells.

Blockade of γ-Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells.

Anticancer research (2019-09-15)
Hiroko Takagi, Hiromi Ii, Susumu Kageyama, Eiki Hanada, Keiko Taniguchi, Taku Yoshiya, Tokuhiro Chano, Akihiro Kawauchi, Susumu Nakata
초록

γ-Glutamylcyclotransferase (GGCT) is highly expressed in many forms of cancer, and is a promising therapeutic target. The present study investigated whether inhibition of GGCT enhanced the antiproliferative effects of the drug docetaxel in prostate cancer cells. Immunohistochemistry and western blot analysis were conducted to measure GGCT expression in prostate cancer tissue samples and cell lines. GGCT was inhibited using RNAi and a novel enzymatic inhibitor, pro-GA, and cell proliferation was evaluated with single and combination treatments of GGCT inhibitors and docetaxel. GGCT was highly expressed in cultured prostate cancer cells and patient samples. GGCT inhibition alone inhibited prostate cancer cell line proliferation and induced cellular senescence. GGCT inhibition in combination with apoptosis-inducing docetaxel had more potent antiproliferative effects than either drug used alone. GGCT inhibition may potentiate anticancer drug efficacy.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
MISSION® esiRNA, targeting human GGCT